Innoviva, Inc. (INVA)
Nasdaq · Healthcare · Biotechnology
$20.64+0.68%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.5B
- P/E (trailing)
- 4.8
- Forward P/E
- 9.3
- 52-week range
- $16.52 – $25.15
- 52-week change
- +19.19%
- EPS (trailing)
- $4.28
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $411M (+14.67%)
- Operating margin
- 39.8%
- Diluted EPS
- $3.30
- Free cash flow
- $196M
From the company’s annual report on SEC EDGAR.
About Innoviva, Inc.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.
Headquarters: Burlingame, United States · 159 employees · inva.com